Tvardi Therapeutics, Inc. (TVRD)

NASDAQ: TVRD · Real-Time Price · USD
26.25
+0.20 (0.77%)
At close: May 9, 2025, 4:00 PM
25.61
-0.64 (-2.44%)
After-hours: May 9, 2025, 4:05 PM EDT
0.77%
Market Cap 239.60M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 9.36M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 19,269
Open 25.86
Previous Close 26.05
Day's Range 25.86 - 26.25
52-Week Range 8.14 - 31.32
Beta n/a
Analysts Strong Buy
Price Target 39.00 (+48.57%)
Earnings Date May 21, 2025

About TVRD

Tvardi Therapeutics, Inc. operates as a biotechnology company that develops medicines for cancer, chronic inflammation diseases, and fibrosis diseases. It develops inhibitors of STAT3, a molecule implicated in the initiation and progression of cancer and fibrosis. Its pipeline includes TTI-101, a small-molecule inhibitor of signal transducers and activators of transcription; and TTI-109, a STAT3 inhibitor for clinical use, including tolerability, bioavailability, and potency. Tvardi Therapeutics, Inc. was incorporated in 2017 and is based in Su... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2017
Country United States
Stock Exchange NASDAQ
Ticker Symbol TVRD
Full Company Profile

Analyst Forecast

According to one analyst, the rating for TVRD stock is "Strong Buy" and the 12-month stock price forecast is $39.0.

Price Target
$39.0
(48.57% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Tvardi Therapeutics Announces Presentation at the American Thoracic Society 2025 Annual Conference

HOUSTON--(BUSINESS WIRE)-- #IdiopathicPulmonaryFibrosis--Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, smal...

4 days ago - Business Wire

Tvardi Therapeutics Announces Closing of Merger with Cara Therapeutics

Merger creates a Nasdaq-listed, clinical-stage biopharmaceutical company – Tvardi Therapeutics – developing novel treatments targeting STAT3 to treat fibrosis-driven diseases.

Other symbols: CARA
24 days ago - GlobeNewsWire